2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

2:30PM-4:00PM: Abstract Number: 3097

Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma (IFNg) Antibody, in Patients with Hemophagocytic Lymphohistiocytosis (HLH)

Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

2:30PM-4:00PM: Abstract Number: 3129

Integrative Analysis of the Colonic Microbiota in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

2:30PM-4:00PM: Abstract Number: 3147

Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

2:30PM-4:00PM: Abstract Number: 3113

Interest of Assessing Anti-Drug Antibodies for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial « Rotation or Change »

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

2:30PM-4:00PM: Abstract Number: 3131

Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics II

2:30PM-4:00PM: Abstract Number: 3096

Interferon-Gamma (IFNg) in Macrophage Activation Syndrome (MAS): CXCL9 Levels As a Biomarker for IFNg Production in MAS

Pediatric Rheumatology - Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases

2:30PM-4:00PM: Abstract Number: 3107

Investigating the Ameliorating Effect of Pregnancy on Rheumatoid Arthritis Using Whole Transcriptome Analysis

Rheumatoid Arthritis - Human Etiology and Pathogenesis III

2:30PM-4:00PM: Abstract Number: 3081

IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8

2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3111

Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy V: Immunogenecity

2:30PM-4:00PM: Abstract Number: 3143

Mapping the Back-Door Routes into the Vascular Wall: 3D Microscopic Reconstruction of Microvasculature in the Normal Temporal Artery and in Giant Cell Arteritis

Vasculitis III

2:30PM-4:00PM: Abstract Number: 3082

Nanogel Based Delivery of an Inhibitor of Calcium/ Calmodulin- Dependent Protein Kinase 4 Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice

2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3148

Physical Activity in Children and Adolescents with Juvenile Idiopathic Arthritis and Associated Factors

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

2:30PM-4:00PM: Abstract Number: 3085

Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus

2015 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3149

Predictors of Longitudinal Quality of Life Impact in Pediatric Localized Scleroderma

ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

2:30PM-4:00PM: Abstract Number: 3138

Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].